Covidien Aneurysm Embolization Device Recall A Class I, FDA Says
This article was originally published in The Gray Sheet
Executive Summary
FDA tagged Covidien’s April 1 recall of its Pipeline aneurysm embolization devices and Alligator retrieval devices as a high risk, class I action.
You may also be interested in...
Covidien Initiates Aneurysm Device Recall
The voluntary recall of Covidien’s Pipeline aneurysm embolization device and Alligator retrieval devices is expected to have a slight negative effect on earnings in the second half of the year, but the impact could increase if it takes longer than expected to replace the affected products, the firm suggested.
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.